JOINT Corp
Close on Oct 19, 2026
- Market cap
- $103.58M
- P/E (TTM)
- 26.9
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $15.20M | $0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $14.80M | $0.09 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 12, 2026 | After market close | $15.20M | $0.07 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $13.40M | $0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $13.30M | $0.01 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $13.10M | $0.05 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | After market close | $14.40M | $0.06 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | After market close | $30.20M | $-0.21 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 6, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| System-wide comp sales for clinics open 13 months or more | 2026 | -3% to 3% growth | Maintained |
| Consolidated Adjusted EBITDAnon-GAAP | 2026 | $12.50M to $13.50M | Maintained |
| New franchised clinic openings, excluding the impact of refranchised clinics | 2026 | 22 to 26 | Lowered |
| System-wide sales | 2026 | $519.00M to $552.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Joint filed with the SEC
The Joint Corp. Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
1NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q2 2026 Financial Results As of June 30, 2026, reported on August 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports First Quarter 2026 Financial Results
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
1NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q1 2026 Financial Results As of March 31, 2026, reported on May 7, 2026
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Signs Asset Purchase Agreement to Sell 45 Corporate-Owned Clinics in Southern California
Other events · EX-99.1 to Form 8-K
The Joint Corp. Reports 2025 Fourth Quarter and Full Year Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
1NASDAQ: JYNT | © 2026 The Joint Corp. All Rights Reserved. | Q4 & Full Year 2025 Financial Results As of December 31, 2025, reported on March 12, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports Third Quarter 2025 Financial Results
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
The Joint Corp. Board of Directors Authorizes
Material agreement · Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
The Joint Corp. Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Expects to Restate Full Year 2024 and First Quarter 2025 Financial Statements due to Overestimated Noncash Impairment Charges
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
“We are executing our plan to become the best and largest pure play chiropractic care franchise system. As part of this strategy, we will deploy capital from the sales of corporate clinics to improve our
Material agreement · Other events · EX-99.1 to Form 8-K
The Joint Corp. Names Business Transformation and Growth Expert
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
The Joint Corp. Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports Fourth Quarter and Year-end 2024 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports 2024 Operating Metrics
Results of operations · EX-99.1 to Form 8-K
The Joint Corp. Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2024 Results As of Sept. 30, 2024 | Reported on Nov. 7, 2024 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Appoints Sanjiv Razdan President and Chief Executive
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Joint Corp. Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q2 2024 Financial Results As of June 30, 2024 | Reported on August 8, 2024 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q1 2024 Financial Results As of March 31, 2024 | Reported on May 2, 2024 EXHIBIT 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q4 2023 Financial Results As of December 31, 2023 | Reported on March 7, 2024 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Q3 2023 Financial Results As of September 30, 2023 | Reported on November 9, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com EXHIBIT 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Welcomes Jeff Gramm to the Board of Directors and Signs Standstill Agreement with Bandera Partners LLC
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
The Joint Corp. Reports Preliminary Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Preliminary Q2 2023 Investor Presentation As of June 30, 2023 | Reported on September 13, 2023 The Joint Corp. | NASDAQ: JYNT | thejoint.com
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
The Joint Corp. Provides Updates on the June 30, 2023 SEC 10-Q Filing
Results of operations · Prior financials no longer reliable · EX-99.1 to Form 8-K
The Joint Corp. Announces Receipt of Delinquency Notification Letter from Nasdaq
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
The Joint Corp. Reports Second Quarter 2023 Operating Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K